Patents Assigned to JÜSTUS-LIEBIG-UNIVERSITÄT GIESSEN
-
Patent number: 10501803Abstract: The present invention relates to a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer, comprising the measurement of the amounts of specific isoforms of GATA6 and/or NKX2-1 in a sample of said subject. Furthermore, the present invention relates to a composition for use in medicine comprising (an) inhibitor(s) of specific isoforms of GATA6 and/or NKX2-1. Additionally, the present invention relates to a kit for use in a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer.Type: GrantFiled: May 21, 2014Date of Patent: December 10, 2019Assignees: MAX-PLANCK GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V., JUSTUS-LIEBIG-UNIVERSITÄT GIESSENInventors: Guillermo Barreto, Aditi Mehta, Indrabahadur Singh, Marten Szibor, Rajkumar Savai, Werner Seeger, Thomas Braun, Andreas Günther, Marcus Krüger
-
Publication number: 20140106379Abstract: The present invention discloses an immunological test for the detection and specific determination of autoantibodies against testicular antigens which are associated with inflammation-related fertility disorders of male mammals in a biological sample of a male mammal, in particular the detection of testicular ER-60 autoantibodies and/or transferrin autoantibodies. The immunological test is utilized to detect the presence of immunologically-caused and infection-related infertility in male mammals, particularly in humans.Type: ApplicationFiled: September 9, 2013Publication date: April 17, 2014Applicant: JUSTUS-LIEBIG-UNIVERSITAT GIESSENInventors: ANDREAS MEINHARDT, MONIKA FIJAK
-
Publication number: 20130267731Abstract: The present invention describes tripodal bisphosphonate derivatives with a flexible basic framework for the functionalisation of surfaces, and methods for their production and use. The central atom of the flexible framework is hereby a tertiary aliphatic carbon atom. A fourth remaining position of the flexible framework is suitable to be optionally functionalised by so-called click reactions, for example with biomolecules, polyethylene glycol or active agents.Type: ApplicationFiled: September 7, 2011Publication date: October 10, 2013Applicant: JUSTUS-LIEBIG-UNIVERSITAT GIESSENInventors: Wolfgang Maison, Elisa Franzmann, Faiza Khalil
-
Publication number: 20130245270Abstract: The present invention describes tripodal catechol derivatives with a flexible basic framework for the functionalisation of surfaces, and methods for their production and use. The central atom of the flexible framework is hereby a tertiary aliphatic carbon atom. The remaining fourth bridgehead position is easily suitable to be further functionalised via so-called click reactions, e.g. with biomolecules, dyes, radiomarkers, polyethylene glycol or active agents.Type: ApplicationFiled: September 7, 2011Publication date: September 19, 2013Applicant: JUSTUS-LIEBIG-UNIVERSITAT GIESSENInventors: Wolfgang Maison, Faiza Khalil, Elisa Franzmann
-
Publication number: 20130217916Abstract: The present invention describes tripodal catechol derivatives with an adamantyl basic framework for the functionalisation of surfaces, and methods for their production and use. A fourth remaining position of the adamantane skeleton is suitable to be optionally functionalised by so-called click reactions, for example with biomolecules, polyethylene glycol or active agents.Type: ApplicationFiled: September 7, 2011Publication date: August 22, 2013Applicant: JÜSTUS-LIEBIG-UNIVERSITÄT GIESSENInventors: Wolfgang Maison, Elisa Franzmann, Faiza Khalil
-
Publication number: 20130165625Abstract: The disclosed invention relates to peptides incorporating 3-aminoadamantane-1-carboxylic acids. These peptides are disclosed as surprisingly possessing neurogenic and neurotrophic properties. These pharmacological activities can advantageously be utilized for restoring or maintaining neuronal function in the CNS. In particular, the compounds can be used for treatment and prophylaxis of neurodegenerative diseases, e. g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, as well as in post-acute traumatic brain injury, or cerebral ischemia.Type: ApplicationFiled: June 22, 2011Publication date: June 27, 2013Applicant: JUSTUS-LIEBIG-UNIVERSITAT GIESSENInventors: Peter R. Schreiner, Lukas Wanka
-
Publication number: 20130095108Abstract: The present invention provides methods for treating interstitial lung diseases, comprising administering to an individual an effective amount of an inhibitor of coagulation factor XII. The invention further provides uses and pharmaceutical kits for that treatment.Type: ApplicationFiled: April 1, 2011Publication date: April 18, 2013Applicant: JUSTUS-LIEBIG-UNIVERSITÄT GIESSENInventors: Ewa Jablonska, Klaus Preissner, Malgorzata Wygrecka
-
Publication number: 20120171658Abstract: The present invention relates to a device and a procedure for the withdrawal, manufacture, storage and transportation of blood products in the widest sense, in particular a closed blood removal, processing and storages system, as well as a system suitable for the administration of medicinal products which are obtained from blood or blood products, and a corresponding procedure for the legally conformant and GMP-compliant preparation, manufacture, storage and transportation of blood products or blood components or blood constituents or blood preparations (within the meaning of the Medical Products Act AMG). The present invention in particular allows the manufacture, storage, transportation and administration of completely aliquoted autologous serum eye drops for direct application to the patient or other drugs manufactured from blood or blood products without the need for clean room laboratories.Type: ApplicationFiled: May 27, 2010Publication date: July 5, 2012Applicant: JUSTUS-LIEBIG-UNIVERSITÄT GIESSENInventors: Gregor Bein, Holger Hackstein, Joachim Misterek
-
Publication number: 20110124912Abstract: The invention at hand describes functionalized diols of diamondoids, in which one of the two hydroxy groups is masked by a protective group, as well as methods for producing these functionalized diols. The protective group is a group —CHR1R2, wherein R1 and R2 stand for alkyl groups and the protective group comprises at least one halogen atom. The monoethers of the diamondoid diols according to the present invention are produced by reacting the diamondoid diol with a halogenated alcohol CHOHR1R2 in the presence of a catalyst acid. The monoetherified diols allow for the targeted production of derivatives of diamondoids, for example, of the corresponding aminoalcohols and aminocarboxylic acids. For that purpose, the diamondoid monoether is reacted in a first step with a halogen nitrile in a Ritter reaction to the corresponding monoether amide.Type: ApplicationFiled: June 2, 2009Publication date: May 26, 2011Applicant: JUSTUS-LIEBIG-UNIVERSITAT GIESSENInventors: Peter R. Schreiner, Hartmut Schwertfeger